MethylGene Oncology Agent Shows Activity In NHL Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.